NOX

1.52%

6.7¢ noxopharm limited

The company's latest patent application, Immuno-Oncology Therapy...

First 14 Last

Share
Profile

Follow
hottod

5,871 Posts.

17434

13/09/21

20:45

Post #: 56032469
Share
Originally posted by RBx ↑

There are some interesting aspects to IONIC that shareholders might like.

Opdivo is approved by the FDA to be dosed either every 2 weeks (240 mg) or every 4 weeks (480 mg), with no apparent difference in efficacy at either dose. If patients require frequent clinical support, it appears that the 2-weekly dose is preferred.

Because IONIC is a clinical trial, and all patients in Cohort 1 will have just failed Opdivo, I expect IONIC patients in Cohort 1 to be treated every 2 weeks with Opdivo so that they can be have maximum clinical support. It makes sense to use the same treatment regime with Cohort 2, which consists of patients with cancers that until now have been unsuitable for Opdivo.

If Opdivo treatment is 240 mg every 2 weeks, it is almost certain that NOX66 will be administered for 7 days on followed by 7 days off. Dosage levels of NOX66 will probably start at 1200 mg, which has already proven safe, and increase in steps.

For the first time, this would result in administration of NOX66 every 2 weeks at high dose levels. The first week will probably be NOX66 alone, to confirm safety, but after that Trial Investigators will be able to monitor the progress of combination treatment every two weeks.

Interesting times.

The IONIC trial has started to screen patients

Expand

The company's latest patent application, Immuno-Oncology Therapy Using Isoflavone Compounds, suggests that the preferred method is either

a 2 weekly treatment cycle with idronoxil dosed daily for the first 10 days and a dose of 240 mg nivolumab on day 2, with no drug administered on days 11 to 14 or

a 4 weekly treatment cycle with idronoxil dosed daily for the first 10 days and a dose of 480 mg nivolumab on day 2, with no drug administered on days 11 to 28.

https://patentscope.wipo.int/search...ab=NATIONALBIBLIO&_cid=P10-KTIBJ4-44454-1
NOX Price at posting: 50.0¢ Sentiment: Hold Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Bitcoin investors need to know the risks

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

There are more pages in this discussion • 1 more message in this thread...

First 14 Last

Add NOX (ASX) to my watchlist

(20min delay)
Last 6.7¢		Change 0.001(1.52%)		Mkt cap ! $19.57M

Open	High	Low	Value	Volume
6.7¢	6.7¢	6.7¢	$818	12.21K

Buyers (Bids)

No.	Vol.	Price($)
1	17790	6.7¢

Sellers (Offers)

Price($)	Vol.	No.
7.0¢	4049	1

View Market Depth

No.	Vol.	Price($)
1	17790	0.067
1	24715	0.066
1	15000	0.065
1	10000	0.064
1	100000	0.062

Price($)	Vol.	No.
0.070	4049	1
0.079	11999	1
0.080	12099	2
0.081	22345	2
0.090	52000	3

Last trade - 15.44pm 12/07/2024 (20 minute delay)

NOX (ASX) Chart

The company's latest patent application, Immuno-Oncology Therapy...

Nimy to raise $1.21M to explore 'newsy' WA targets

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Immutep reports strong response rate from immunotherapies treating carcinomas

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Bitcoin investors need to know the risks

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The company's latest patent application, Immuno-Oncology Therapy...

Top Stories

Nimy to raise $1.21M to explore 'newsy' WA targets

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Immutep reports strong response rate from immunotherapies treating carcinomas

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Bitcoin investors need to know the risks

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News